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Vascular growth forms the ﬁrst functional organ system during development, and continues
into adult life, wherein it is often associated with disease states. Genetically determined
vasculogenesis produces a primary vascular plexus during ontogenesis. Angiogenesis,
occurring, e.g., in response to metabolic stress within hypoxic tissues, enhances tissue
capillarization. Arteriogenesis denotes the adaptive outgrowth of pre-existent collateral
arteries to bypass arterial stenoses in response to hemodynamic changes. It has been
debatedwhether vasculogenesis occurs in the adult, andwhether or not circulating progen-
itor cells structurally contribute to vessel regeneration. Secondly, themajor determinants of
vascular growth – genetic predisposition, metabolic factors (hypoxia), and hemodynamics –
cannot be assigned in a mutually exclusive fashion to vasculogenesis, angiogenesis, and
arteriogenesis, respectively; rather, mechanisms overlap. Lastly, all three mechanisms of
vessel growth seem to contribute to physiological embryogenesis as well as adult adaptive
vascularization as occurs in tumors or to circumvent arterial stenosis. Thus, much concep-
tual and terminological confusion has been created, while therapies targeting neovascu-
larization have yielded promising results in the lab, but failed randomized studies when
taken to the bedside. Therefore, this review article aims at providing an exact deﬁnition
of the mechanisms of vascular growth and their contribution to embryonic development
as well as adult adaptive revascularization.We have been looking for potential reasons for
why clinical trials have failed, how vitally the application of appropriate methods of mea-
suring and assessment inﬂuences study outcomes, and how relevant, e.g., results gained
in models of vascular occlusive disease may be for antineoplastic strategies, advocating a
reverse bedside-to-bench approach, which may hopefully yield successful approaches to
therapeutically targeting vascular growth.
Keywords: vascular growth, vasculogenesis, angiogenesis, arteriogenesis
INTRODUCTION
In vertebrate organogenesis, the blood vessels constitute the ﬁrst
organ system that arises and reaches a functional state (Risau and
Flamme, 1995); a prerequisite for the growth of complex organ-
isms which develop an increasing need for oxygen and nutrients
and the removal of metabolicwaste products.Mice failing to estab-
lish a functioning circulatory system by E10 die shortly thereafter
(Semenza, 2007b).
Vascular growth continues into adult life, either in the form
of cyclic processes such as decidual arteriogenesis, or in response
to acute or chronic stress, as occurs in atherosclerotic vascular
disease, chronic inﬂammation or the hypoxic environment of
growing malignancies, or in response to physical training (Hänze
et al., 2007). Most major causes of disease in humans involve
changes in tissue vascularization andoxygen availability (Semenza,
2007b).
The recent decades have seen an evolutionof ourunderstanding
of the (patho)physiology that underlies vascular growth,providing
a rationale for intense efforts toward either its therapeutic stim-
ulation or inhibition. This requires a thorough understanding of
the underlying mechanisms.
In this systematic review article we discuss key mechanisms of
vasculogenesis, angiogenesis, and arteriogenesis, the three major
processes of vascular growth. We thereby set out to provide a basis
for understanding current therapeutic strategies which target the
vascular system.
BASIC MECHANISMS OF VASCULAR GROWTH:
VASCULOGENESIS, ARTERIOGENESIS, AND ANGIOGENESIS
VASCULOGENESIS
The formation of the earliest blood vessels (around embryonic
day E18 in humans, E6.5 in mice) occurs through vasculoge-
nesis in all mammals. Vasculogenesis comprises mesoderm for-
mation, the establishment of the endothelial cell (EC) lineage as
so-called angioblasts, their organization into cord-like vascular
structures, lumen formation, and the organization of early vessels
into vascular networks (Figure 1A).
During gastrulation, the three germ layers ectoderm, meso-
derm,and endodermare formed,of which themesodermgives rise
to the vascular system as well as the primordial blood cells (Risau
and Flamme, 1995). Mesodermal differentiation to ECs occurs
ﬁrst within the extraembryonic visceral mesoderm of the yolk sac
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FIGURE 1 |Vasculogenesis, angiogenesis, and arteriogenesis. During
vasculogenesis (A), (hem-) angioblast precursors form blood islands (a), which
subsequently differentiate into primary ECs (b), and early blood cells (c). The
resulting primary vascular plexus (d) matures into a secondary vessel network
(e). Angiogenesis (B) denotes the growth of capillaries, mostly in response to
a lack in sufﬁcient tissue supply with oxygen and nutrients that is signaled by
a growth factor gradient (B). Capillary sprouts (f) grow from pre-existent
vessels (g) in the direction of a growth factor gradient (e.g., VEGF) that is
sensed by a tip cell (h) and followed by a vascular stalk (i) that subsequently
lumenizes. Arteriogenesis describes the outgrowth of pre-existent arteriolar
collaterals which then bypass an arterial stenosis (C). Atherosclerotic
occlusion of a major conductance artery induces a pressure gradient between
the collateral stem region (k) (approx. 100mmHg) and the reentry zone (l)
(approx. 25mmHg), followed by a redistribution of perfusion, an increase in
collateral ﬂow and a subsequent outgrowth of the collateral arteriole of typical
corkscrew-like morphology (m).
(splanchnopleuric mesoderm) around developmental days E6–
7 in mice (reviewed in Jin and Patterson, 2009), and shortly
afterward within the embryo (somatopleuric mesoderm) at the
one-somite stage. Additional, atypical regions of EC formation
have been described in avian as well as mammalian embryos, such
as placental (Demir et al., 2007) or allantoic tissues (Caprioli et al.,
2001). EC differentiation, both in the yolk sac and within the
embryo proper, occurs in form of blood islands or – islets, cellular
aggregates whose peripheral cells are destined to become EC pre-
cursors, while their centers form blood cells (Risau and Flamme,
1995; Carmeliet, 2000; Figure 1A).
Already in the late nineteenth century, His (1900) described
as “angioblasts” the mesenchymal cells that later form blood ves-
sels. Murray (1932) renamed these cells “hemangioblasts,” as he
assumed that ECs and blood cells would always develop from the
same progenitor cell.
Indeed, in the extraembryonic visceral mesoderm of the yolk
sac, endothelial, and hematopoietic progenitors are closely related
(Sabin, 1917; Choi et al., 1998; Eichmann et al., 2000). Genuine
hemangioblasts have been isolated from both mouse and zebraﬁsh
embryos and give rise to both vascular ECs aswell as hematopoietic
cells (Huber et al., 2004; Vogeli et al., 2006).
However, the blood islands forming within the intraembryonic
mesodermand the earlier extraembryonic vasculogenic aggregates
of the yolk sac differ.While extraembryonic hemangioblasts are (at
least) bipotential progenitors, angioblast differentiationwithin the
embryo is not coupled as closely to the development of the blood
cells (Risau and Flamme, 1995). Rather, a hemogenic EC inter-
mediate, i.e., an EC of hematopoietic potential, later generates
hematopoietic cells (Lancrin et al., 2009).
Recent results suggest an even more complex picture. ECs
share a progenitor cell with a number of different cell popula-
tions which give rise to the cardiovascular system, not only blood
cells, but also cardiomyocytes, and vascular smooth muscle cells
(SMCs; Jin and Patterson, 2009). Transdifferentiation seems pos-
sible between these organ-speciﬁc mesodermal progenitors (Song
and Tuan, 2004; Mudumana et al., 2008).
Angioblast differentiation from mesodermal cells and the
formation of immature blood vessels from angioblasts have
together been deﬁned as vasculogenesis (Risau and Flamme,
1995), followed by lumen formation and network maturation
(Figure 1A).
Precise mechanisms of lumen formation have been eluci-
dated for epithelia, but remain somewhat ambiguous for vascular
endothelia. The peripheral cells of the blood islands, destined to
become ECs, ﬂatten and proceed to surround primitive liquid-
ﬁlled spaces, which fuse, forming the ﬁrst lumina in form of
angioblastic cords/strands. Once a lumen has been generated,
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angioblastic cords originating from blood islands in spatial prox-
imity associate to form a primary embryonic vascular network
(Hirakow and Hiruma, 1981). Migratory angioblasts (Flamme
et al., 1997; Risau, 1997) assemble along the posterior axis to
form the precursors of the main body vasculature, i.e., the dor-
sal aorta, cardinal veins, and primary endocardial tubes (Flamme
et al., 1997).
Thus, vasculogenesis leads to the formation of the earliest
primary vascular network, which consists of the precursors of
major vessels and the honeycomb-like plexuswhich connects them
(Yancopoulos et al., 2000).
Known molecular pathways of vasculogenesis constantly
increase in number and complexity, and are beyond the scope
of this article. In short, molecular signals from neighboring tis-
sues interact with the mesoderm during vasculogenesis, examples
of which are Hedgehog protein originating in the hypochord
and VEGF from the ventral somites (Jin and Patterson, 2009). If
endo- and ectodermal signals are critical, is still debated. Fibrob-
last growth factors (FGFs), transforming-growth factor β family
members (TGFβ-like factors), andVEGF-Amay inducemesoderm
formation anddifferentiation (Green et al., 1992; Isaacs et al., 1992;
Duan et al., 2003). However, Risau and Flamme (1995) collected
ample evidence of the mesoderm alone being capable of vascular
differentiation.
With the emergence of the angioblast the molecular picture
becomes more clear, with leading roles taken on by (a) the
Angpt/Tie and (b) the VEGF signaling pathways.
TheVEGF family comprises seven different molecules (VEGF1
throughVEGF7,PIGF),which act via the tyrosine kinasesVEGFR1
(Flt1), VEGFR2 (Flk1, KDR), VEGFR3 (Flt4), and their corecep-
tors Neuropilin-1 and -2. Embryonic defects in VEGF signaling
lead to antenatal lethality due to early and fundamental defects
in endothelial and hematopoietic development (Shalaby et al.,
1995). Current candidates for the superordinate regulation of
VEGF signaling during vasculogenesis are HoxB5 and FoxH1 (Jin
and Patterson, 2009).
Angiopoietins 1–3, via their Tie-2 receptor, regulate the late
vasculogenic processes, vascular network development, and vessel
maturation (Schnurch and Risau, 1993).
It is debated whether vasculogenesis occurs in postnatal life
(Luttun and Carmeliet, 2003; Péault, 2010). On the one hand, cells
sharing molecular characteristics of embryonic hemangioblasts,
namely CD34/VEGF-2R coexpression, have been detected in the
adult circulation (Pelosi et al., 2002). Factors such as VEGF,
GM-CSF, bFGF, and IGF-1 mediate their mobilization and/or
differentiation (reviewed in Carmeliet, 2000). Other authors,
however, assign vasculogenesis to a restricted time period in
early embryogenesis (Hänze et al., 2007; Semenza, 2007b)
and state that the use of the term “vasculogenesis” for adult
blood vessel development, hypothetically associated with cir-
culating vascular progenitor cells, was ”an inappropriate use
of this term based on its natural deﬁnition” (Ferguson et al.,
2005).
Although environmental factors modify the vasculogenic pro-
gram in the embryo, genetic predetermination governs vasculoge-
nesis.
ANGIOGENESIS
Angiogenesis denotes capillary growth either by sprouting from or
by splitting of pre-existing vascular structures (intussusception)
(Risau, 1997).
Sprouting angiogenesis is initiated by a proteolytic degradation
of the extracellular matrix (ECM) by EC in response to proan-
giogenic factors such as VEGF released in their proximity, e.g.,
in response to local hypoxia. ECs proliferate and migrate toward
gradients of proangiogenic factors, form lumina, and vessels are
stabilized, mature, and acquire tissue-speciﬁc properties (Risau,
1997; Carmeliet, 2000; Fischer et al., 2006; Figure 1B).
While sprouting angiogenesis relies on EC mitosis and migra-
tion, intussusceptive growth multiplies vessels by splitting their
lumina by the insertion of tissue pillars (Patan, 2000). Intussus-
ception subsumes a series of processes, extensively reviewed in
(Djonov and Makanya, 2005). Vessel maturation is comparable to
the events observed in sprouting angiogenesis, which this chapter
mainly focuses on.
During development, angiogenesis establishes a functional cir-
culation in primarily avascular tissues.While vasculogenesis forms
the primary vascular plexus in endo- and mesoderm-derived
organs, ectoderm-derived tissues such as the brain are vascularized
by angiogenesis (Pardanaud et al., 1989).
Physiological angiogenesis is a highly ordered and tightly con-
trolled process critically dependent (a) on a controlled interac-
tion of the proliferating endothelium with its environment and
(b) orchestrated by an interplay of cytokines and growth factors
(Chung et al., 2010).
Sprouting angiogenesis is initiated by vascular leakage and
local degradation of the basement membrane (BM) of the mother
vessel. A preceding NO-mediated local increase in vascular diam-
eter has especially been described for pathological angiogenesis
(Carmeliet, 2000). Leaking plasma proteins then form a scaf-
fold for migrating ECs in a PECAM-1/VE-Cadherin/Src kinase-
mediated process (Eliceiri et al., 1999). VEGF leads to vasodilation
and increased permeability.
The angiopoietin Angpt-1, through interaction with its speciﬁc
receptor Tie-2, counteracts vasodilation to prevent excess leak-
age. Its physiological antagonist Angpt-2 destabilizes the matrix,
with a subsequent partial degradation of the BM and surround-
ing ECM as well as proteolytic activation of angiogenic growth
factors (Carmeliet, 2000). Angpt-2 activated MMPs and prote-
olytic enzymes liberate matrix-bound pro- and antiangiogenic
mediators in an orchestrated sequence, and regulate the biological
activities of factors such as VEGF by proteolytic cleavage (Fischer
et al., 2006).
Next, some ECs acquire an activated phenotype, which permits
mitosis and migration. The “initial decision of an EC to become
angiogenic” (Carmeliet, 2000) potentially involves factors such as
p54, the vascular endothelial zinc ﬁnger-1 and the Hox and GATA
families (Carmeliet, 2000). In the current biomedical literature, no
uniform deﬁnition of an activated endothelium can be found. The
term is used to refer to, e.g., an upregulation of adhesionmolecules
in response to inﬂammatory mediators or hemodynamic forces or
the acquisition of an angiogenic phenotype,which is what we refer
to herein.
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Angiogenesis is induced by a pioneering “tip cell” which
increases BM and ECM degradation by membrane-type 1 MMP
expression and secretion (Figure 1C). Thereby, more ECs loose
contact to the BM and interact with exposed tissue collagen,which
induces a reorganization of the actin cytoskeleton and sprout
formation (sprouting morphogenesis; Chung et al., 2010). Aus-
prunk and Folkman (1977) described mitosis and migration in
angiogenesis,withmigration predominating at the tip of the grow-
ing capillary and mitosis occurring several cells proximal to the
tip. Selection of tip cells vs. stalk cells depends on intracellular
VEGFR1/VEGFR2 ratios, with ECs dynamically competing for the
tip cell position (Jakobsson et al., 2010).
Leaked plasma proteins serve as a matrix for EC migration. ECs
interact with the matrix in an integrin-mediated process. Sprout-
ing ECs are guided by gradients of angiogenic factors such as
VEGFs/VEGFR2. VEGF isoforms fulﬁll different functions during
angiogenesis: context-speciﬁcally, they increase vascular perme-
ability, aid ECM degradation and pericyte recruitment and induce
EC sprouting, proliferation, migration, lumen formation, and EC
survival (for a detailed review, see Chung et al., 2010 or Ferrara
et al., 2003).Hypoxia drives angiogenesis through intracellular sta-
bilization of the hypoxia-inducible factor (HIF-1) and subsequent
induction of VEGF expression.
The HIFs are transcription factors (HIF-1, -2 and -3) which
are induced when partial pressures of tissue oxygen decrease
to values below 6%/40mmHg (Semenza, 2007a). HIFs are het-
erodimers of a regulatory α subunit and a constitutive β subunit
(Wang and Semenza, 1995). Cellular HIF levels are regulated in a
complex manner, involving prolyl-4-hydroxylases and asparaginyl
hydroxylases, phosphorylation and sumoylation (Hänze et al.,
2007; Scholz and Kirschner, 2011). Transcriptional activation
of HIF-1 occurs downstream of protein-kinase C mediated sig-
naling pathways, in response to stimuli such as inﬂammatory
mediators or angiotensin II (Hänze et al., 2007). HIF-1α trans-
lation is enhanced downstream of the PI3K/Akt pathway, while
post-transcriptional control of HIF-1α synthesis may be rele-
vant during vascular growth and remodeling (Gorospe et al.,
2011).
Hypoxia-inducible factor-1 assumes a central role in oxygen-
dependent vascularization via binding to the hypoxia-responsive
cis elements [5′(A/G)CGTG-3′] within the promoter regions (Rey
and Semenza, 2010) of genes associated with vessel growth and
remodeling. HIF-1 is essential for proper embryonic vascular
development, regulating angiogenic growth factors such as VEGF,
PLGF, and the Angiopoietins and their coordinated activation
(Semenza, 2007b).
The FGFs family and their tyrosine kinase receptors (FGFR)
stimulate angiogenesis. FGFs 1, 2, 4, and 5 target ECs and exert pro
angiogenic activities in vivo, directly or through the recruitment
of proangiogenic cells (Fischer et al., 2006).
Angpt-1/Angpt-2 mediate the balance between vascular qui-
escence and proliferation during the sprouting/migration phase
of angiogenesis. Local Angpt-2 expression, together with VEGF,
appears to be critical for EC reentry into the cell cycle. Angpt-1
is mitogenic and chemotactic for sprouting ECs, while Angpt-2 is
not (Witzenbichler et al., 1998; Yancopoulos et al., 2000).
Targeted tip cell migration is aided by PIGF via VEGFR1
(Autiero et al., 2003; Fischer et al., 2006). Disruption of this path-
way causes defects in the stress response toward hypoxia in the
adult, as in ischemia, inﬂammation or malignancies (Carmeliet
et al., 2001).
Many other molecules are pro- or antiangiogenic, often
context- and/or tissue-speciﬁcally (Semenza, 2007b), and reach
beyond the scope of this paper. Examples are integrins and their
receptors, tissue-speciﬁc growth factors, erythropoietin, and inter-
leukins (Carmeliet, 2003; Kertesz et al., 2004; Fischer et al., 2006;
Sciesielski et al., 2010).
Leukocytes affect angiogenesis. Monocytes/macrophages func-
tion as cellular regulators of angiogenesis, recruited by chemokines
(Bernardini et al., 2003), VEGF-A or PIGF to sites of active
angiogenesis (Barleon et al., 1996) to exert subpopulation-speciﬁc
effects (Carmeliet, 2003).
Both vasculogenesis and angiogenesis lead to chord-like EC
alignments (Zeeb et al., 2010), from which vascular networks are
formed by fusion, anastomosis, and lumen formation. Although
large amounts of in vitro data have been compiled, functional
models of lumenization have only recently been suggested: appar-
ently, angiogenic sprouts form lumina by cell or cord hollowing
(Iruela-Arispe andDavis,2009). Either, intracellular vacuoles asso-
ciate, or ECs form cylinders,which subsequently create an internal,
extracellular lumen.
Until recently, angiogenesis was thought to proceed via cell
hollowing, generating seamless tubes (Iruela-Arispe and Davis,
2009). Since Sabin (1917) had described coalescing vacuoles,mod-
ern techniques, especially in cell and tissue culture, led to the
discovery of EC lumen formation by a pinocytosis-resembling
process (depending on integrin and cdc42/Rac1 downstream of
integrin–ECM signaling interactions; Bayless and Davis, 2002),
which could analogously be observed in vivo in the zebraﬁsh
(Kamei et al., 2006). However, lumen formation seems to dif-
fer in health and disease, sprouting and lumen formation occur
either at the same time or in sequence, and pathways appear to be
context-speciﬁc. Vacuolation-based lumenization has, for exam-
ple, especially been observed for isolated ECs deprived of cell–cell
contacts (Iruela-Arispe and Davis, 2009). Recent data have been
tipping the scales in favor of the extracellular lumen model. A
closer look at zebraﬁsh vasculogenesis revealed that ECs form a
multicellular tube (Blum et al., 2008).VEGF is necessary for lumen
formation (Iruela-Arispe and Davis, 2009). Angpt-1 increases ves-
sel diameter, while Thrombospondin-1 and tubedown-1 reduce
it (Fischer et al., 2006). Once functional vessels have been gen-
erated, mechanical factors displace genetic pre-speciﬁcations in
determining lumen diameter (Jones et al., 2006).
Angiogenic vascular morphogenesis enters its resolution phase
when the activated, proteolytic phenotype of the invading tip cell
is “turned off” by EC-pericyte contacts. Tip cell MMP activity
is downregulated and replaced by an activation of its inhibitors
TIMP-2 and -3 (Saunders et al., 2006). An involvement of Dll4–
Notch1 in restricting tip cell formation in response to VEGF-A
has been described (Hellström et al., 2007). A downregulation of
major angiogenic factors such as VEGF, and a rise in local levels of
PDGF, Angpt-1, and TGFβ1, occur (Chung et al., 2010).
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Mature blood vessels are made of ECs and mural cells (per-
icytes, SMCs) within a matrix. Following early angiogenesis, no
mural cells are present, and homotypic tight and adherens junc-
tions resist blood ﬂow (Iruela-Arispe and Davis, 2009). When
mural cells are recruited and a BM, elastic laminae, and surround-
ing matrices are generated (Jain, 2003; “vessel maturation”), the
newly generated vessel stabilizes.Vessels then specialize to fulﬁll the
requirements of their host tissue by EC differentiation (Carmeliet,
2000; Jain, 2003). Not only the individual vessel, but vascular net-
works acquire their functionality through patterning events such
as branching, remodelling and pruning (“network maturation”)
(Jain, 2003).
To tighten and stabilize the vessel (a) mural cells are recruited
and (b) matrix and laminae are formed.
PDGF (-BB), via PDGF-Rβ1 on mural cells, regulates pericyte,
and SMC recruitment (Lindblom et al., 2003). Similarly, Angpt-1
on mural cells interacts with Tie-2 on ECs. Both are involved in
the tightening of the EC layer, conferring leakage-resistance. SIP-
1/EDG-1 interactions mediate mural cell recruitment and matrix
production (Kluk and Hla, 2002). The latter is also stimulated by
the TGFβ/Alk-5 pathway (Jain, 2003).
Network maturation processes occur concomitantly or sequen-
tially. Pruning, the removal of superﬂuous vascular branches, is
mediated by tissue oxygen tension (Chung et al., 2010).Directional
branching or secondary outgrowth can be guided by mechan-
ical forces transmitted by the ECM (Krishnan et al., 2008) via
integrin-dependent pathways (Jain, 2003; Chung et al., 2010). The
ECM generates extracellular growth factor gradients for branch-
ing, in which proteases (e.g., MMPs) and their inhibitors (e.g.,
TIMPs, ADAM) play a major role by cleaving and activating
angiogenic factors (VEGF, FGF, angiostatin; Jain, 2003; van Hins-
bergh and Koolwijk, 2008). Growth factors relevant for neuronal
growth share roles in angiogenic network maturation, e.g., the
neuropilins (Neufeld et al., 2002), ephrins, or theDll4/Notch path-
way (Djokovic et al., 2010). Other network remodeling factors are
VEGF/VEGFR3, theEts family of transcription factors and gridlock
in zebraﬁsh (Carmeliet, 2000).
Vessel specialization involves the development of organ-speciﬁc
ECcharacteristics andnetwork-relatedprocesses such as arteriove-
nous (AV) fate determination. Most processes are context-speciﬁc,
such as the VEGF-mediated EC fenestration in endocrine glands
(Jain, 2003) or theGFAP/angiotensinogen interaction in the devel-
opment of the blood–brain barrier (Carmeliet, 2000). During the
development of the arterial system, vessels are “muscularized”
(Carmeliet, 2000; “arterialization”): pericytes/SMCs grow along-
side the nascent vessel, or differentiate in situ from mesenchymal
precursors.
Some authors refer to this process as arteriogenesis. This may
lead to confusion, as “arteriogenesis”had been coined byW. Risau,
W. Schaper, and R. Munoz-Chapuli (Schaper et al., 1999) for the
postnatal development of collateral conductance arteries from
arteriolar networks. Arteriogenesis, in this review, will only be
used in the latter sense.
When a functional, local vascular network has developed, tissue
oxygenation provides a negative feedback loop for angiogenesis.
Unlike vasculogenesis, angiogenesis is not only well-established
in the adult organism (Risau, 1997), but numerically the main
mechanism through which new vessels arise (Carmeliet, 2000).
Adult angiogenesis resembles embryonic angiogenesis (Risau,
1997), both are facilitated by reductions in oxygen tension, but
adult angiogenesis requires additional events: cell-cycle progres-
sion, remodeling of cell adhesions and junctions, induction of pro-
teolysis, and neutralization of angiogenesis inhibitors (Carmeliet,
2000) differ between angiogenesis seen in the embryo and in the
adult. Egginton and Gerritsen (2003) have systematically reviewed
the events that specify embryonic angiogenesis: ECs are more
mitotic, early angiogenic sprouts contain a subpopulation of EC
precursors that display an invasive migratory behavior, intercellu-
lar junctions are readily formed, and nascent embryonic capillaries
are characterized by wide lumina and fenestrated endothelia.
Deregulated angiogenesis has a major pathophysiological
impact. Cancer, atherosclerosis, infectious diseases, psoriasis, and
diabetes involve changes in tissue capillarization with signiﬁcant
consequences on morbidity and mortality. Therapeutic attempts
are being made to (a) induce angiogenesis, mostly through the
targeted application of proangiogenic growth factors, and (b) to
apply angiogenesis inhibitors.
Angiogenesis occurs during embryonic development and in
the adult organism. In contrast to embryonic vasculogenesis, and
although angiogenesis is co-determined by genetic factors, it is
a change in tissue oxygenation that induces angiogenesis, mainly
through its master regulator, VEGF.
ARTERIOGENESIS
Angiogenesis is initiated by hypoxia, and leads to a capillary vas-
cular network. Arteriogenesis, in contrast, is the outgrowth of a
mature collateral arteriole upon stenosis or occlusion of a major
conductance artery (Figure 1D), driven by hemodynamic factors
such as an increase in stretch and/or ﬂuid shear stress (FSS) on
ECs (Schaper and Ito, 1996; Carmeliet, 2000).
Stenosis or occlusion of a conductance vessel trigger arterio-
genesis (Figure 1D): with an arterial occlusion, a pressure gradient
develops over interconnecting collaterals between the pre- (high
pressure areal) andpostocclusive (lowpressure areal) regions. Flow
through these collateral vessels increases and deforms ECs, raising
FSS on the endothelium, which functionally and morphologically
activates it. Shear patterns need to be pulsatile to prompt an arte-
riogenic response and support arterial identity through molecular
factors such as Gja5 (connexin 40; Buschmann et al., 2010).
An activated endothelial phenotype results from increases in
ﬂow,morphologically characterized byEC swelling andultrastruc-
tural protrusions (Schaper et al., 1976, 1988; Bondke et al., 2008),
correlated with an increased cellular metabolism, changes in pro-
tein expression, and the activation of transient receptor potential
cation channels, which affect cellular osmotic control and volume
regulation, and upon chronic stimulation, EC and SMC prolifer-
ation (Bondke et al., 2008; Troidl et al., 2009) reviewed in (van
Royen et al., 2010).
Changes in glycocalix structure prompt EC–leukocyte interac-
tions (Grundmann et al., 2009).
Shear-activatedECs attractmononuclear cells (Bergmann et al.,
2006) by expression of MCP-1 and ICAM-1, which invade the
vessel wall and facilitate its proteolytic remodeling (Hillmeister
et al., 2008).
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Whether or not endothelial progenitor cells (EPCs) contribute
structurally to postnatal vascular growth is unclear (Shintani et al.,
2001; Ziegelhoeffer et al., 2004). Probably, their function is in line
with macrophage function in arteriogenesis, i.e., the provision of
local factors that facilitate vascular remodeling (Grundmann et al.,
2007a; Patenaude et al., 2010).
By ECM digestion and remodeling, monocytes enable SMC
dedifferentiation to a synthetic, proliferative phenotype, SMC
migration, proliferation, and division. The media of the growing
vessel undergoes a dramatic phenotypic change. Elastic laminae
become digested, and SMC proliferation leads to an outgrowth of
the growing collateral to about 50-fold increases in tissue volume
(Scholz et al., 2000).
Arteriogenesis has been investigated meticulously since the
1970s, owing at large to the work of W. Schaper and his stu-
dents from Bad Nauheim, while recent research on the molecular
pathways of arteriogenesis sheds new light on the process.
Endothelial cells sense elevated FSS levels by mechanosensory
complexes upstream of integrin signaling (Tzima et al., 2005).
Transcription factors activator protein 1 (AP-1), early growth
response protein 1 (Egr-1), and other DNA binding proteins
are activated via the Rho- and MEK/Erk-1/-2 pathways, while
actin-binding proteins, integrins, and connexins assume impor-
tant functions (reviewed in Schaper, 2009). Rho controls the
expression ICAM-1 and MCP-1. Integrins act as upstream effec-
tors of Rho (Deindl, 2007). Carp, differentially expressed during
arteriogenesis, may function as an upstream regulator of Egr-1
(Deindl, 2007). As is true for other processes of vascular growth,
the identiﬁed factors are speciﬁc for species and tissues.
However, a number of unifying principles apply to arteriogenic
processes (Schaper, 2009).
First, collateral conductance vessels develop from pre-existent
arterioles. Arteriogenesis does not increase the number of collat-
erals. Detection by imaging yields ambiguous results when vessels
grow from below detection level during the observation period to
an above-threshold size (Limbourg et al., 2009; Schaper, 2009).
Moreover, assessment of collateralization may be easier in the
periphery than in the myocardium due to spatial limitations and
close anatomical relations in the latter.
Second, arteriogenesis occurs outside the ischemic area at risk.
In peripheral arterial disease (PAD) in human patients, femoral
artery occlusion leads to ischemia of the lower leg, while collater-
als develop in parallel to the stenosis (Yang et al., 2008; van Royen
et al., 2010). Stenosis of one of the vessels supplying the Circle of
Willis in the brain leads to a redistribution of blood ﬂow and sub-
sequent collateral enlargement outside the ischemic area (Busch
et al., 2003). In themyocardium, the ischemic area and the growing
collateral lie close together, however, the stem of collaterals, “the
most important single factor in determining the extent and dis-
tribution of myocardial infarction” develops outside the ischemic
area (Fulton,1964).Growing collaterals conduct arterial blood and
are thus sufﬁciently supplied with oxygen (van Royen et al., 2010):
Hypoxia-inducible gene expression is not relevant for collateral
growth (Ito et al., 1997; Deindl et al., 2001). VEGF expression
occurs (Toyota et al., 2005; Schaper, 2009), however, independent
of the angiogenic HIF–VEGF-axis, while hypoxia impairs mono-
cyte migration (Grimshaw and Balkwill, 2001). In the zebraﬁsh,
where sufﬁcient oxygenation canbemaintained by diffusion alone,
adaptive arteriogenesis occurs in response to changes in ﬂow (Gray
et al., 2007).
Third, arteriogenesis is initiated by changes in blood ﬂow. The
vascular wall is constantly subjected to changes in stretch, cyclic
mechanical strain, and shear stress, with shear stress primarily
affecting the EC layer, while stretch acts on all layers of the ves-
sel wall (Lehoux and Tedgui, 2003). The steep pressure gradient
between the pre- and poststenotic areas is bridged by collateral
vessels, in which the sudden increase in ﬂow leads to signiﬁ-
cantly rising shear rates. This brings about the structural and
functional changes in EC morphology and function that initiate
arteriogenesis (Schaper, 2009).
Angiogenesis is terminated when local tissue oxygenation is
restored (Chung et al., 2010). A similar negative feedback control
mechanism applies to arteriogenesis: in adaptive arteriogenesis,
the restoration of conductance by collateral growth ceases when
FSS normalizes, thereby achieving a restoration of blood ﬂow
capacity of 30–40% (Schaper, 2009; Figure 1C). This “adaptive
arteriogenesis” leads to a species-dependent 2- to 20-fold enlarge-
ment of collateral arterioles (Schaper and Ito, 1996; Schaper,
2009).
Collateral vessel development varies signiﬁcantly between indi-
viduals (Rehman, 2008). Arteriogenesis may eliminate the signs
and symptoms of a severe vascular occlusion such as a complete
occlusion of a main coronary artery (Schaper, 1971; Grundmann
et al., 2007a), but may also remain ineffective due to individ-
ual differences, e.g., in the expression of antiarteriogenic genes
(Schirmer et al., 2008). Arterial occlusions often occur in patients
who (a) have one or more cardiovascular risk factors or (b)
regularly take cardiovascular drugs, both of which inﬂuence arte-
riogenic capacity. Hypercholesterolemia, hypertension, tobacco
use, hyperglycemia, obesity, and advanced age all impair collat-
eral development (reviewed in de Groot et al., 2009). Risk factor
reduction by medication may counteract these effects, however,
antiarteriogenic effects of some antiplatelet agents (Hoefer et al.,
2005;Duelsner et al., 2011) are due to their anti-inﬂammatory side
effects.
Adaptive arteriogenesis occurs in the adult organism, and can
be stimulated to overcome its physiological restrictions to induce
or enhance arteriogenesis in patients with vascular occlusive dis-
ease (therapeutic arteriogenesis). Two therapeutic focus points
have emerged: the augmentation of monocyte migration and sub-
sequent vascular remodeling through the application of growth
factors, and the sustained elevation of FSS as the mechanical
stimulus for the induction of collateral growth.
The critical role of monocytes and pro-inﬂammatory cytokines
(Buschmann et al., 2003) for adaptive arteriogenesis yields a num-
ber of candidates for its therapeutic stimulation. Proarteriogenic
cytokines aimat a prolongation of monocyte life span, augmenting
monocytemigration into the vessel wall and subsequent SMCpro-
liferation. Concern has been expressed for most of this substances,
as their effects seem to overlap with atherosclerotic disease mech-
anisms (Janus phenomenon; Epstein et al., 2004; Grundmann
et al., 2007a). A detailed analysis of the mechanisms involved is
most important for the safe and efﬁcient pharmacological and/or
hemodynamic augmentation of arteriogenesis.
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Substances that have been proarteriogenic in preclinical studies
are MCP-1, the colony-stimulating factors GM-CSF and G-CSF,
TGFβ1, FGFs and, to a certain degree, VEGF. MCP-1 enhances
collateral conductance in PAD, but showed proarteriogenic side
effects (van Royen et al., 2003). G-CSF and GM-CSF are attrac-
tive pharmacological targets, as safety and dosage data in human
subjects are available from their use in the treatment of leucope-
nia. GM-CSF promotes arteriogenesis in the brain (Schneeloch
et al., 2004; Love, 2003), the myocardial vasculature (Seiler et al.,
2001), and the periphery (Grundmann et al., 2006). G-CSF has
yielded similarly promising ﬁrst results in the brain (Sugiyama
et al., 2011) and heart (Deindl et al., 2006), respectively. TGFβ1
augments collateral growth in animalmodels of PADand coronary
stenosis, even when applied locally (Grundmann et al., 2007b).
However, a deregulation of the TGFβ cascade is implied in the
progression of atherosclerosis, necessitating more research. FGF-2
stimulates arteriogenesis in the heart and periphery (Grundmann
et al., 2007a). In addition, there are some conﬂicting data on the
role of exogenous VEGF in promoting arteriogenesis in the heart
(van Royen et al., 2010).
Collateral growth can be stimulated by enhancing and/or sus-
taining elevated FSS levels on the endothelium. Arteriovenous
(AV) shunts lead to a sustained FSS level, wherein collateral
growth and increasing collateral conductance generate a positive
feedback mechanism. High shunt ﬂows can overcome the physi-
ological restrictions of arteriogenesis, leading to a normalization
and overcompensation of maximal conductance (Pipp et al., 2004;
Eitenmüller et al., 2006). Besides advancing our understanding of
the basic mechanisms of arteriogenesis and of establishing bench-
marks for therapies, the results from shunt models translate into
practical application. For decades, mechanisms to non-invasively
increase FSS have been known, namely the beneﬁcial effects of
physical training on patients with atherosclerotic diseases, prob-
ably even before Heberden (1772) reported an alleviation of
exercise-induced angina pectoris by sawingwood each day.During
adaptive collateral growth the restoration of ﬂow brought about
by the growing collateral reduces FSS and prematurely terminates
arteriogenesis. Exercise training maintains elevated FSS level, thus
augmenting collateral proliferation (reviewed in Bondke Pers-
son et al., 2011). External counterpulsation is currently under
evaluation for the clinical use in patients who are unable to
undergo the necessary long and intense training intervals, with
promising ﬁrst results (Buschmann et al., 2009; Thakkar et al.,
2010).
Unfortunately, therapeutic neovascularization has not found its
way to large-scale clinical application (Grundmann et al., 2007a;
Rehman, 2008). This is probably due to a number of reasons:
First, individual differences seem to be decisive. In a large
study population, Wustmann et al. (2003) found 20–25% of
patients with functional collaterals able to prevent all signs
of myocardial ischemia during coronary occlusion, indicating
a complex genetic predisposition that acts in favor of adap-
tive collateral growth, while it fails in others. Second, adequate
endpoints and sufﬁcient methods of assessment are critical. If,
for example, Laser Doppler ﬂow measurements alone are uti-
lized, they will not provide a thorough characterization of the
extremity’s angioarchitecture, as superﬁcial vessels contribute
overproportionally to the results. Other obstacles include, e.g.,
the difﬁculty to blind studies with growth factor administra-
tion due to the side effects of the medication (van Royen et al.,
2010). Therefore, intense further research seems necessary before
therapeutic neovascularization will be applicable in the clinical
setting.
Arteriogenesis counteracts the narrowing of an adult con-
ductance artery. In contrast to the genetic program for vas-
culogenesis, and changes in tissue oxygenation for angiogenic
processes, mechanical factors, mainly changes in blood ﬂow,
regulate arteriogenesis.
PHYSIOLOGY AND PATHOPHYSIOLOGY OF COMPLEX
VASCULAR GROWTH PROCESSES
BLOOD VESSEL GROWTH AND DEVELOPMENT
The growth of blood vessels is an integral part of embryonic devel-
opment. In adult life, it is often related to pathologic processes,
such as the vascularization of neoplastic tissue or the organ-
ism’s attempt at compensating for an arterial stenosis (Figure 2).
Three major growth processes, vasculogenesis, angiogenesis, and
arteriogenesis, and their main determinants, i.e., genetic predis-
position, oxygen tension, and hemodynamic forces, have been
introduced.Vascular growth processes in vivo –within the embryo,
in growing collaterals or in tumors – usually comprise more
than one of these mechanisms. Thus, an interplay of genet-
ics, hemodynamics, and oxygen tension determines vessel iden-
tity, morphology, and function during ontogenesis and in adult
life.
Genetic hardwiring controls embryonic vessel formation, iden-
tity, and positioning (Jones et al., 2006). However, the signiﬁcant
FIGURE 2 |The tumor and the embryo. Rapid cell division leads to
exponential tissue growth both during the growth of the mammalian
embryo as well as in malignant tissues. Basic mechanisms of vascular
growth occur both during normal development and tumor growth: vessel
growth is promoted by the expression of angiogenic factors.When
adequate oxygenation can no longer be warranted by diffusion, hypoxia, in
addition, activates the angiogenic cascade.With the onset of ﬂow,
hemodynamics shape the developing vasculature.
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interindividual differences in, e.g., the ability to form collaterals in
response to environmental factors in adult life indicates a role of
genetic predetermination also later in life.
The physical environment modiﬁes vessel morphology and
function, examples of which are the hypoxic induction of angio-
genesis and the initiation of arteriogenesis by hemodynamic fac-
tors. The picture is rendered more complex by the fact that
although one environmental factor has essentially been associ-
ated with one growth mechanism, they overlap: tissue oxygen
tension is essentially associated with angiogenesis, but inﬂuences
both vasculogenesis and arteriogenesis (Semenza, 2007b), and
hemodynamic factors such as ﬂow determine embryonic vessel
identity (Jones et al., 2006), branching morphogenesis of angio-
genic sprouts (Carmeliet, 2000), and arteriogenic EC activation
(Bondke et al., 2008; Troidl et al., 2009).
A thorough understanding of how these events occur and
how they are controlled is a critical prerequisite for therapeutical
interventions that aim at (neo-)vascularization.
EMBRYOGENESIS
During embryogenesis, vasculogenesis and primary remodeling
processes give rise to a vascular plexus, in which arteriovenous
identity is established andprimarymaturation takes place. Second,
the embryonic vascular network is optimized to hemodynamic
and functional efﬁciency (Jones et al., 2006; Rey and Semenza,
2010).
During the initial phase, vasculogenesis predominates, tightly
controlled by genetic determination (Jones et al., 2006; Semenza,
2007b; Jin and Patterson, 2009). This phase is dominated by cel-
lular differentiation and decreasing plasticity (Jin and Patterson,
2009). A primary vascular plexus is formed rather stereotypically
(Semenza, 2007b). TheVEGF family and the angiopoietins assume
a leading role, others are the Wnt and Delta/Notch pathways,
the ephrins, growth factors such as TGFβ and FGF as well as a
number of transcription factors (reviewed in Jin and Patterson,
2009).
Factors guiding vascular development are shared with the ner-
vous system (Carmeliet and Tessier-Lavigne, 2005). Tip cells are
functional equivalents to the axonal growth cone, following repul-
sive or attractive signals. VEGF and the netrin receptor unc-5
homolog b (UNC5B) are prominent examples of such guidance
cues, while Dll4/Notch signaling is in control of tip cell differ-
entiation (Le Noble et al., 2008). The genetic regulation of AV
identity before the onset of blood ﬂow is determined by signal-
ing molecules such as Neuropilin-1 and Notch1 for arteries and
Neuropilin-2 and Ephrin B4 for veins.
Environmental inﬂuences do not signiﬁcantly determine ini-
tial vascular plexus generation, but hemodynamics (Lucitti et al.,
2007) and tissue oxygenation (Ramírez-Bergeron et al., 2004;
Semenza, 2007b) modulate early vasculogenesis (Jin and Patter-
son, 2009). The role of HIF in earliest vascularization is still
debated: HIF-1α knockout mice are lethal due to early vascular
remodeling defects, while mice embryos subjected to constant
hypoxia develop normally (Lucitti et al., 2007). On the other
hand, factors critically involved in early vasculogenesis such as
VEGF and TGFβ are major HIF-1α target genes (Jin and Patter-
son, 2009), and deletion of theHIF-beta subunit (ARNT) results in
defective hematopoiesis and the inhibition of both vasculogenesis
and angiogenesis (Ramírez-Bergeron et al., 2006).
As soon as the heart starts pumping blood through the primary
circulation, ﬂow contributes to the initial remodeling processes
that affect embryonic vessels. In this phase, the primary vascu-
lar plexus is remodeled to a secondary one (Patan, 2000). Car-
diac failure in mice during development leads to severe early
remodeling defects, and ﬂow-induced eNOS expression seems
to control secondary plexus generation (Lucitti et al., 2007).
Vasculogenesis is supplemented or replaced by hypoxia-induced
angiogenesis. The capillary network that forms within the indi-
vidual tissues is much more individual-speciﬁc then the pri-
mary vascular plexus (Semenza, 2007b), indicating environmental
inﬂuences.
AV determination is a model process in which environmental
factors determine vascular form and function before a genetically
determined background. Feedback signals from vascular function
(pressure, ﬂow, metabolic state of the tissue) modify the genet-
ically determined outline after the onset of blood ﬂow. Without
ﬂow, the expression of speciﬁc AV markers in the yolk sac vascu-
lature is not sufﬁcient to induce differentiation, while perfusion
with venous blood transforms an early artery into a vein (Le
Noble et al., 2008). Local tissue hypoxia suppresses the arterial
markers Delta-like 4 (Dll4) and Ephrin B2 (Claxton and Fruttiger,
2005).
In this regard, the embryonic development of pre-existent col-
lateral arteries remains elusive. Differentiation and maturation of
the arterial system during development occurs in a proximal-to-
distal direction, forming the arterial tree (Schaper and Schaper,
2004). Collateral arteries, however, are devoid of a clear proximal-
to-distal axis. It has been shown that collaterals continue to
develop in postnatal life, by arterialization of a capillary connec-
tion of two arteriolar endings (Price et al., 1994). It is tempting
to presume a similar mechanism for the embryonic period, but
it has until now not been demonstrated. However, as inhibition
of artery formation occurs when a maturing artery approaches
the irrigation domain of a neighboring branch (Durán et al.,
1998), the disinhibition of these not yet known signaling path-
ways may contain clues to how pre-existent collaterals develop
and why they differ between individuals (Schaper and Schaper,
2004).
Until the onset of circulation, vascular development is genet-
ically determined. Environmental factors such as hemodynamics
and oxygen tension then contribute signiﬁcantly to the remodel-
ing events that shape the individual-speciﬁc, secondary vascular
plexus.
VASCULAR OCCLUSIVE DISEASE
Atherosclerosis, a systemic disease of the vascular system, leads
to progressive narrowing and occlusion of conductance arteries, a
major cause of morbidity andmortality worldwide.Arterial occlu-
sionprompts an adaptive response of the organisms to compensate
for perfusiondeﬁcits.While acute changes in ﬂowand tissue perfu-
sion are counteracted by changes in vascular tone, chronic stenoses
lead to adaptive vascular growth. Downstream of the stenosis,
reduced perfusion leads to ischemic hypoxia. HIF-1 is upregu-
lated, VEGF and other angiogenic factors are secreted, inducing a
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capillary proliferation within or in the border zone of the ischemic
tissue (Wagner et al., 2002; Semenza, 2007b). However, stenosis of
a conduit artery cannot be compensated for by capillary growth:
according to the law of Hagen and Poiseuille, the number of cap-
illaries needed to compensate for the lost conductance capacity
would leave no more room for the non-vascular tissue that is to
be supplied (Scholz et al., 2001).
Arteriogenesis occurs upstream of and in time with ischemia-
induced angiogenesis (Figure 3). In different animal models, arte-
riogenesis was the most efﬁcient mechanism to increase blood
ﬂow to an ischemic region (Scholz et al., 2002). Therapies aiming
at the restoration of arterial blood supply must therefore target the
proximal conduit vessel (Carmeliet and Tessier-Lavigne, 2005).
Arteriogenesis, as a homeostatic mechanism, is switched off
when FSS normalizes, as does angiogenesis when tissue oxygen
tensions have reached physiologic values (Semenza, 2007a). This
may occur before perfusion is restored sufﬁciently. Therefore, ther-
apeutic arteriogenesis aims at an augmentation of the naturally
occurring adaptive response.
Arteriogenesis is not related primarily to changes in oxygen
tension (Deindl et al., 2001). It affects vessels that are continu-
ously perfused with oxygenated arterial blood (van Royen et al.,
2010) upstream of the ischemic area at risk. Interestingly, how-
ever, experimental administration of a constitutively active form
of HIF-1α positively inﬂuenced angiogenesis as well as arterio-
genesis in a hindlimb ischemia model (Patel et al., 2005). HIF-1α
polymorphisms are associated with individual differences in coro-
nary collateralization (Resar et al., 2005) and the role of VEGF in
coronary arteriogenesis is still debated (van Royen et al., 2010).
Interestingly, one of the properties of angiogenic cytokines is
the mobilization and recruitment of heterogeneous bone-marrow
derived cells (Grunewald et al., 2006). This observation prompted
the assumption that vasculogenesis would be a part of the postna-
tal adaptive response to ischemia. However, vasculogenesis as such
is not regulated by oxygen gradients (Semenza, 2007b), and the
cells detected in the postnatal circulation and recruited to sites of
vascular remodeling are often inﬂammatory in nature (Semenza,
2007b) and not incorporated into growing collaterals, but rather
support vessel wall remodeling, as monocytes do (Deindl and
Schaper, 2005). Angiogenic cytokines might contribute to their
recruitment and proarteriogenic action.
While angiogenesis inhibitors have made it to clinical applica-
tion, the administration of individual proangiogenic factors alone
or in combination has so far not yielded results that would justify
their use in a larger patient population (Semenza, 2007b). Unfor-
tunately, the induction of arteriogenesis through growth factor
administration, although more than promising in animal models,
has also not yet reached the clinics. Reasons for that might lie in
the multifactorially impaired response to ischemia in patients that
calls for multifactorial therapies, the necessary individual risk fac-
tor management and differences in genetic background (Semenza,
2007b) as well as the sensitivity of assessment methods that had
been available so far for the use in human subjects (van Royen
et al., 2010). Considering the biophysics of oxygenated blood ﬂow
in case of an arterial stenosis, a focus on the restoration of super-
ordinate arterial inﬂow is critical, which should then be followed
by an attenuation of the distribution within the ischemic area.
FIGURE 3 | Adaptive vascular growth in peripheral arterial disease
(PAD).The pathophysiology of PAD is a suitable example of the interplay of
different mechanisms partaking in adaptive vascular growth. Arterial inﬂow
is usually compromised by a proximal (iliac or femoropopliteal) stenosis of
one of the arteries that supply the lower extremity. Ischemia endangers and
damages the distal (infrapopliteal) region. Hypoxia in the lower leg triggers
an angiogenic response in the border zone of the ischemic tissue, which,
however, cannot compensate for the loss of pulsatile arterial inﬂow. If
sufﬁcient collateral arterioles are present to circumvent the proximal
stenosis, however, an increase in ﬂow triggers their outgrowth, developing
a biological bypass through arteriogenesis.
Further research will be necessary to elucidate the related
pathophysiological mechanisms, while special attention must be
paid to appropriate assessment techniques and endpoints.
In vascular occlusive disease, angiogenesis occurs within the
ischemic tissues in an attempt to compensate for the lack in tissue
oxygen.Arteriogenesis, leading to the positive outward remodeling
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of collateral arteries upstream of the ischemic tissue, is capa-
ble of restoring arterial inﬂow and must thus be at the focus of
therapeutic approaches.
MALIGNANT TUMORS
The size and aggressiveness of solid malignancies depends on
their vascularization. Vascular growth in tumors shares features
of physiological angiogenesis during development (Figure 2). Tis-
sues grow until the delivery of oxygen and nutrients by diffusion
is no longer possible. Then, hypoxia initiates the angiogenic cas-
cade, ensuring oxygen and nutrient supply. During development,
the restoration of tissue oxygen tension shuts down the angiogenic
cascade, and vessels mature to meet speciﬁc demands of their host
tissue. Malignant growth, however, is accompanied by an almost
unlimited, uncoordinated proliferation of vascular tissues (Chung
et al., 2010), which leads to blood vessels that differ from their
physiological counterparts (Figure 4).
Current research efforts have focused on the distinguishing
characteristics of tumor vessels, aiming at targeted therapies (Nagy
et al., 2009). Tumor blood vessels do not exhibit the conventional
hierarchy of the vascular system. They are distributed unevenly, are
tortuous and leaky and comprise AV shunts without an obvious
feeding function. Interestingly, ﬂow directions may vary. Despite
the continuous growth of the tumor vasculature, tumors tend to
outgrow their blood supply. Vessel density is generally higher at
the interface with the host organism, all of these factors indicating
inefﬁcient growth, which is conﬁrmed by the lower overall blood
ﬂow in tumors when compared to normal tissues.
The formation of tumor blood vessels roughly follows the three
physiological mechanisms of vascular growth discussed above,
however, signiﬁcant aberrations occur.
Vasculogenesis denotes the de novo generation of blood ves-
sels from immature progenitor cells, an issue still debated for
the adult organism. EPCs have been observed in the adult blood-
stream, in conjunction with growing malignancies, and have even
FIGURE 4 |Tumor arteriogenesis/angiogenesis. Malignant neoplasms
often critically depend on the development of an autonomous vascular
system, which differs from physiological vascular tissue. Tumor vessels are
devoid of a conventional arterial–venous hierarchy, unevenly distributed,
often irregularly enlarged (a), leaky and often insufﬁcient. Even in
vascularized tumors, hypoxic regions develop (shaded areas). Interestingly,
however, some tumor vessels share features of growing collateral arterioles
in arteriogenesis, examples being their tortuosity (b) and the presence of
perivascular macrophages (c). On a cellular and subcellular level, basement
membrane degradation, SMC dedifferentiation, and growth factor proﬁles
further indicate tumor arteriogenesis.
been suggested to be surrogate markers of cancer progression
and chemotherapeutic efﬁcacy (Patenaude et al., 2010). While the
existence of bone-marrow derived EPC that structurally incor-
porate into the tumor vasculature is indicated by a number of
high-quality studies, the relevance of this phenomenon for cancer
progression remains controversial.
In addition, (sub-)populations of cancer cells are apparently
able to aid tumor vascularization through a mechanisms called
“vasculogenic mimicry,” namely the physical drilling of blood-
conducting tunnels (Maniotis et al., 1999), which are primarily
devoid of ECs, but mimic EC behavior to such an extent, that cell
lines derived from these tissues have mistakenly been considered
to be of endothelial origin (Moldovan et al., 2000). In later stages,
endothelialization takes place (Ribatti and Vacca, 2009). Vasculo-
genic mimicry occurs in different cancer types and stages, and is
currently met with much interest as a mechanisms that determines
therapeutic sensitivity and invasiveness.
Tumor angiogenesis has been a therapeutic target since the
suggestion of antiangiogenic chemotherapy 40 years ago (Folk-
man,1971).When the growing tumor reaches a critical dimension,
hypoxia upregulates mediators such as the HIFs, which then tran-
scriptionally activate the proangiogenic cascade via, e.g., theVEGF
family and its co-players. Moreover, uncoordinated secretion of
proangiogenic factors occurs, driven by oncogenes, by tumor sup-
pressor inactivation etc. (Dvorak, 2003). VEGF-A, which assumes
a central role in tumor angiogenesis (Nagy et al., 2009;Chung et al.,
2010), has, together with its receptor, until now been at the center
of attention. However, drugs targeting VEGF-A are costly, have
serious adverse effects, and have until now only been shown to be
effective as part of an aggressive combined therapeutic regimen
(Jain et al., 2006).
Searching the extensive biomedical databases for“tumor arteri-
ogenesis” still yields only a handful of peer-reviewed publications.
However, if one has a closer look at tumor vascularization, fea-
tures of collateral growth, as described for adaptive arteriogenesis,
seem to fabricate the feeding vessels of growing malignancies. It
appears that in the hunt for innovative cancer therapies, tumor
arteriogenesis has been somewhat neglected, but may be of great
value as a therapeutic target.
Tumor vessels are tortuous and enlarged (Nagy et al., 2009;
Chung et al., 2010). In this, they bear a striking resemblance to
growing collateral arteries, which proliferate in response to an
immediate pressure gradient. Thus, tumor vessels assume aspects
of a growing collateral which are so characteristic that they have
been deﬁned as arteriogenesis’ distinguishing features (Schaper
and Schaper, 2004).
Capillarization, especially of highly vascularized tumors, leads
to a decrease in vascular resistance over the feeding vessel, fol-
lowed by an increase in blood ﬂow, which increases FSS on its
endothelium,as occurs in growing collaterals of a vascular stenosis.
Indeed, “tumor arteriogenesis” has been postulated (Yu and Rak,
2003), and the enlargement of feeding tumor vessels with increas-
ing tumor capillarization has been observed (Folkman, 1997).
The ultrastructure of growing tumor vessels strikingly resembles
that of growing collateral arteries. Mother/feeding vessel forma-
tion requires BM degradation, pericyte detachment, and vascular
enlargement (Nagy et al., 2009). These processes similarly occur
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in growing collateral arterioles of the extremities and the heart
(Schaper, 1971), although in adaptive arteriogenesis, the process
is, unsurprisingly, ordered and controlled: the thin-walled collat-
erals of the ﬁrst phase of collateral development are subsequently
stabilized and matured. Tumor vessels may remain in a disor-
dered state (Nagy et al., 2009). Transient SMC dedifferentiation
has been observed in tumor vessels as well as in adaptive collat-
eral growth. The resulting feeder arteries and draining veins are
often endowed with a complete, multilayered pericyte/SMC coat,
have lost VEGFR2, no longer depend on VEGF-A and survive
indeﬁnitely withoutVEGF-A (Nagy et al., 2009). This may explain
the fact that anti-VEGF/VEGFR damage tumors at early stages
of development, but not at later stages when their vessels contain
mature, SMC-coated vessels (Bergers et al., 2003). An inhibition
of PDGF, however, blocked the further growth of late-to-end-
stage tumors, and was, in combination with VEGF inhibitors,
more effective against all stages of experimentally induced pan-
creatic carcinoma (Bergers et al., 2003). Although PDGF has been
detected in the pericyte layer of tumor feeding vessels, the exact
mechanism of action is not clear. PDGF may play a role in the
attraction of progenitor cells to growing tumor vessels, thereby
promoting their growth, and that this may be where the PDGF-
inhibition proves effective. However, taking into account that
(a) the structural contribution of progenitor cells to adult vas-
cular proliferation remains elusive (Patenaude et al., 2010) and
that (b) PDGF mediates collateral proliferation in adaptive arte-
riogenesis (Wu et al., 2010), an alternative explanation for its
effects on solid tumor vascularization would be the inhibition of
tumor arteriogenesis that complements antiangiogenic treatment
by VEGF-inhibition.
Macrophages assume a critical role within the tumor environ-
ment. Macrophagocytic cells are educated by the tumor environ-
ment as tumor-associated macrophages (TAMs), to be able to
promote tumor invasion and metastasis by facilitating cell motil-
ity, matrix degradation and tumor vessel growth (Pollard, 2004).
Thus, they co-determine prognosis and therapeutic results. The
pivotal role of macrophages in angiogenesis has been described
(Carmeliet, 2003), in tumor microenvironments, they produce
and release VEGF and an array of proangiogenic cytokines and
trophic factors (Pollard, 2004). They can assume a critical role
in vascular mimicry, namely the drilling and endothelialization
of vascular tunnels into the tumor tissue (Vacca and Ribatti,
2011).
However, arteriogenesis is the one mechanism of vascular
growthwhich critically depends onmacrophage function (Schaper
et al., 1976; Schaper and Schaper, 2004; Bergmann et al., 2006).
VEGF, abundantly expressed in tumor tissues, stimulates arte-
riogenesis by activating monocytic cells and stimulating their
endothelial adhesion and transmigration (Heil et al., 2000).
Given that tumor arteriogenesis has beenunderestimated, research
efforts to elucidate the contribution of arteriogenesis to tumor
vascularization and the cellular mediators involved therein will
hopefully be an important step in the therapeutic approach against
one major scourge of humanity.
Targeting the tumor vasculature is a critical step in cancer
chemotherapy, but current results are limited and side effects
are signiﬁcant. A thorough look at the individual contribution
of the different vascular growth processes to tumor vasculariza-
tion (angiogenesis, arteriogenesis) may allow for more targeted
approaches.
CONCLUSION AND PERSPECTIVE
Vascular growth fabricates the ﬁrst working organ system dur-
ing organogenesis, and continues throughout life. Vasculogenesis,
angiogenesis, and arteriogenesis are the three major processes
through which vessels grow, each one occurring in response to
a principal stimulus of genetic or environmental origin: vasculo-
genesis is determined genetically, decreased oxygen levels initiate
angiogenesis, and increased ﬂow gives rise to arteriogenic growth.
All three growth processes contribute to embryonic growth and
postnatal adaptive vascular proliferation, in response to, e.g., the
stenotic narrowing of an artery or the expansion of a malignant
neoplasm,making vascular growth processes a tempting therapeu-
tic target. However, benchmarks raised in the lab have until now
not been met by the results achieved at the bedside. It may prove
helpful to go back to the lab to accurately distinguish between
vasculogenesis, angiogenesis, and arteriogenesis contributing to
the disease in question. When we overcome the borders of the
individual biomedical disciplines, to, e.g., apply the current knowl-
edge about arteriogenesis to re-examine how tumor vessels grow,
we may signiﬁcantly advance today’s research results as well as
tomorrow’s health.
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